T-MAXIMUM Biosciences Achieves Dual Milestones: MT026 Data Published in Nature Communications and MT027 Granted FDA IND for Phase II Trial in Recurrent Glioblastoma
Maximum Biology
Developer of Novel Immunotherapy Technologies
CAR-TThe birth of cell therapy has brought a disruptive breakthrough in the treatment of hematological tumors, and it remains one of the hottest fields in innovative drug development. Currently, globally...2000ArticleCAR-TIn the pipeline, tackling solid tumors and developing off-the-shelf universal productsCAR-TIs an important breakthrough direction.
Recently, Suzhou Maoxing Biotechnology Co., Ltd., which is committed to the development of universal cell therapies, announced that itsGeneral TypeCAR-TDual Milestone Achievements in Cell Therapy for Solid Tumors: On the one hand,2026At the start of the year,Independently developed by the companyIL-13Rα2Targeted Universal TypeCAR-TCell TherapyMT026TreatmentRecurrent High-Grade GliomaOfIPhase Clinical Research Data, Published in Internationally Renowned Academic JournalsNature CommunicationsOfficially Published Online; on the other hand,Just last month,Another core pipeline of the company——B7H3Targeted Universal TypeCAR-TCell TherapyMT027, has been approved by the United StatesFDAApproval for the Treatment of Recurrent GlioblastomaIIPhase Clinical Study。The simultaneous progress of the two major pipelines fully validates the scientific foresight of Suzhou Maoxing Biotechnology Co., Ltd.'s universal technology platform and its strong pipeline incubation capabilities, marking a solid and crucial step forward in its journey to conquer solid tumors, the "ultimate fortress" of cell therapy.
MT026：Clinical Data Publication
Specifically, in1Month6Published onNature CommunicationsResearch Paper in the Journal(Title:Intrathecal CRISPR-edited allogeneic IL-13Ra2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial）In China, Suzhou Maoxing Biotechnology Co., Ltd. provided a comprehensive reportMT026Results of Clinical Trials for the Treatment of Recurrent High-Grade Glioma.
ThisBy Suzhou Maoxing Biotechnology Co., Ltd.Professor Huang Yulun's team from the Fourth Affiliated Hospital of Soochow UniversityJointly CompletedThe study focused on a patient population for whom all previous standard treatments had failed and who had a very short life expectancy.Core Data ShowcasesMT026The Breakthrough Potential:In the enrolled5In the case of patients, it was observed that80%Objective Response Rate, including1Complete Remission and3Partial response to treatment. More crucially, no adverse events occurred throughout the treatment process.≥3Grade treatment-related adverse events, severe cytokine release syndrome, neurotoxicity, or graft-versus-host disease,Significant safety features. Starting from tumor recurrence and enrollment, the median overall survival of patients reached13.1Months`, bringing new hope to this extremely difficult-to-treat patient population.`
MT027: ObtainFDA IIClinical Trial Approval
InMT026While completing the proof of concept, another core pipelineMT027It has also achieved key regulatory milestones. Based on its solid technical platform and clinical data,United StatesFDAApprovedMT027EnterIIPhase clinical research, used for the treatment of recurrent glioblastoma.This milestone progress has enabledMT027Among the Global Solid Tumors“Off-the-Shelf”The Leading Group in Cell Therapy Research and Development, whose international multicenter clinical research is about to commence.
As an "off-the-shelf" product derived from healthy donors (off-the-shelf) Product,MT027Can achieve large-scale production and cryopreservation, allowing patients to receive treatment promptly without waiting after diagnosis, thereby securing a precious treatment window period for saving lives.
Moreover, it is worth mentioning that, unlike the lentivirus or retrovirus vectors commonly used in the industry,MT027In the critical phase towards the pivotal clinical trial, a key technological leap has been completed — establishment and finalization ofNon-viral Gene Editing Process, further improve the safety of the product, and enhance the precision and controllability of the preparation process, representing the next generationThe Development Direction of Cell Therapy Processes.
Dual Pipeline Clinical Advancement Demonstrates the Strong Capabilities of a Universal Technology Platform
Founded in2017Suzhou Maoxing Biotechnology Co., Ltd. is a company in China that specializes in universal typeCAR-TOne of the pioneers in the field. This timeMT026AndMT027Behind the continuous breakthroughs are its clear and firm strategic choices and solid technical platform accumulation.
In terms of clinical needs,Since its inception, the company has steered clear of the crowded hematological tumor track,Targeting solid tumors with extremely poor prognoses and limited treatment options, such as glioblastoma. The breakthrough in these two major pipelines is precisely the payoff for this "tough bone" strategy.
In terms of technical layout,Facing AutologousCAR-TCell therapy faces long preparation cycles and patients in the treatment of solid tumorsTChallenges such as inconsistent cell quality have always been faced by Suzhou Maoxing Biotechnology Co., Ltd.Firm“Off-the-shelf”Allogeneic UniversalCAR-TDevelopment of Cell Therapy, aiming to achieve immediate product availability, consistent quality, and cost control. In contrast to the current buzz aroundIn vivoCAR-TAnd other technologies(Dependent on intravenous administration, it is difficult to cross the blood-brain barrier to reach the lesion.), its universal typeCAR-TWith more potential advantages in the treatment of intracranial tumors.
In the development of innovative platforms,Suzhou Maoxing Biotechnology Co., Ltd. relies on its fully independent intellectual property rightsGene-Edited Allogeneic Immune Cell Platform, successfully overcoming the graft-versus-host disease and immune rejection issues in allogeneic cell therapy, achieving CAR-TLong-term survival and efficacy of cells in patients. The core modules of this platform in gene editing strategies, production processes, and quality control systems can be relatively quickly adapted to different targets, enabling rapid pipeline layout and iteration.
MT026AndMT027The synchronous breakthrough demonstrates the high modularity and scalability of Suzhou Maoxing Biotechnology Co., Ltd.'s universal technology platform. Based on the same technical platform,The company has also started to develop universalCAR-TCell therapy expands to more disease areas in urgent need of effective treatment solutions, such as lung cancer and brain metastases of breast cancer.。
Suzhou Maoxing Biotechnology Co., Ltd. stated that the company plans to launch at least one product within the next three years and advance multiple products into clinical trials. II In the research phase, providing new options for patients with solid tumors that lack treatment methods.
"Frontier π" Column
PharmaCube Pro